Effects of obesity and weight loss in PsA. Very significant benefit, OR of MDA 6.67 for 10%+ weight loss @AlexisOgdie @RheumNow #RNL2024 https://t.co/130KAucPl7

• https://twitter.com/RichardPAConway/status/1751286947048530251/photo/1

GRAPPA recommendations 2021 Guide therapy by the active domains, filter by co-morbidities @AlexisOgdie @RheumNow #RNL2024 https://t.co/C1RQAM8DrI

• https://twitter.com/ericdeinmd/status/1751286792383316345/photo/1

Dr. @AlexisOgdie reviews the updated GRAPPA guideline and changes since 2015. #RNL2024 @RheumNow https://t.co/N2HAmlLj83

• https://twitter.com/uptoTate/status/1751286656370393173/photo/1
• https://twitter.com/uptoTate/status/1751286656370393173/photo/1

"In patients with IBD, don't treat with drugs that don't work in IBD." @alexisogdie on why common sense should prevail @rheumnow #RNL2024

How to define "severe" disease? Erosions, multi-site involvement, affecting ADLs/QoL - @AlexisOgdie @rheumnow #RNL2024 https://t.co/gc8bSeSTyJ

• https://twitter.com/KDAO2011/status/1751286321878856162/photo/1

2018 ACR/National Psoarasis Foundation Guidelines for Treatment of PsA - Created helpful definitions of Severe PsA and Severe PsO #RNL2024 @RheumNow @AlexisOgdie https://t.co/kH4UzlEWxA

• https://twitter.com/ericdeinmd/status/1751285980949074218/photo/1

Clinical pearl alert! Check out https://t.co/rvkKlJ8mtk. This site can help you with your PsO decision tree and will be updated again this year. @AlexisOgdie also shares her personal decision tree when approaching patient care while emphasizing shared decision making. #RNL2024… https://t.co/GFYjHw2hgF https://t.co/I8xpekFmYk

• Penn Inflammation Arthritis Program
• https://twitter.com/i/web/status/1751285808714125618
• https://twitter.com/uptoTate/status/1751285808714125618/photo/1

“TNFi, IL17i, JAKi--- note that these are the only classes of drug that work for axial spondyloarthritis!” – Dr. @AlexisOgdie noted ustekinumab, apremilast, and abatacept do not work for inflammatory back pain. @rheumnow #RLN2024 https://t.co/BHV6qCUdYi

• https://twitter.com/KDAO2011/status/1751284524401541408/photo/1

#RNL2024 @RheumNow @AlexisOgdie Many therapies for SpA - but ONLY TNFi, IL17i, and JAKi for AxSpA Check out https://t.co/V7JGc6t72C to help guide treatment decisions: Prior therapies? enthesitis? concomitant IBD/uveitis? comorbidities? Pt preferences? https://t.co/hfFikMs9YL

• Penn Inflammation Arthritis Program
• https://twitter.com/ericdeinmd/status/1751284292934652105/photo/1

Thinking of joint, skin, axial disease in psoriatic arthritis and extra-articular manifestations leading to shared decision making, Alexis Ogdie #RNL2024 @RheumNow https://t.co/F57sEicht7

• https://twitter.com/synovialjoints/status/1751284160235278534/photo/1
• https://twitter.com/synovialjoints/status/1751284160235278534/photo/1

Evolution of treatment landscape in PsA by @AlexisOgdie @RheumNow #RNL2024 https://t.co/ut1e5Z2CjK

• https://twitter.com/RichardPAConway/status/1751283927296405875/photo/1

Cognitive framework for selecting therapy in PsA by @AlexisOgdie @RheumNow #RNL2024 https://t.co/ZepkyA0mWj

• https://twitter.com/RichardPAConway/status/1751283675629846895/photo/1

@AlexisOgdie discusses the current and expected future SpA therapeutic options. However, and I also discuss this with my patients, we are more limited in AxSpA vs PsA (with axial disease.) #RNL2024 @RheumNow https://t.co/dlVgWblSXy

• https://twitter.com/uptoTate/status/1751283587876519948/photo/1

Importance of focusing on patient goals in psoriatic arthritis, use shared decision making and apply the clinical guidelines and treatment options within this context, Alexis Ogdie #RNL2024 @RheumNow https://t.co/jCFWUqJNn3

• https://twitter.com/synovialjoints/status/1751283054360838306/photo/1
• https://twitter.com/synovialjoints/status/1751283054360838306/photo/1

Functional outcomes of immune aging. Connie Weyand. #RNL2024 @RheumNow https://t.co/ZLL7N30n13

• https://twitter.com/NoufAhmedAlham2/status/1751282836395507881/photo/1